Suven Life Sciences, a bio-pharmaceutical company focused on discovering, developing and commercialising novel pharmaceutical products, has received two product patents from Eurasia and one from Canada for the treatment of disorders associated with neurodegenerative diseases and these patents are valid through 2027.

The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and schizophrenia.

With these new patents, Suven has a total of 10 granted product patents from Canada and 12 granted product patents from Eurasia. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at phase-I or phase-II.

Venkat Jasti, CEO, said, “We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally.”

Currently, the company has 12 internally-discovered therapeutic drug candidates in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and obesity in addition to developmental candidate SUVEN-502 for Alzheimer's disease and schizophrenia.